Neue Strategien in der Asthmatherapie

Zurück zum Zitat Buhl R, Berdel D, Criee CP, Gillissen A, Kardos P, Kroegel C et al. Guidelines for diagnosis and treatment of asthma patients. Pneumologie 2006;60:139–77CrossRefPubMed Buhl R, Berdel D, Criee CP, Gillissen A, Kardos P, Kroegel C et al. Guidelines for diagnosis and treatment of asthma patients. Pneumologie 2006;60:139–77CrossRefPubMed

Zurück zum Zitat Kerstjens HA, Disse B, Schroder-Babo W, Bantje TA, Gahlemann M, Sigmund R et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011;128:308–14CrossRefPubMed Kerstjens HA, Disse B, Schroder-Babo W, Bantje TA, Gahlemann M, Sigmund R et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011;128:308–14CrossRefPubMed

Zurück zum Zitat Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367:1198–207CrossRefPubMed Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367:1198–207CrossRefPubMed

Zurück zum Zitat Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med 2015;3:367–76CrossRefPubMed Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med 2015;3:367–76CrossRefPubMed

Zurück zum Zitat Lommatzsch M, Virchow JC. Severe asthma: definition, diagnosis and treatment. Dtsch Arztebl Int 2014;111:847–55PubMedCentralPubMed Lommatzsch M, Virchow JC. Severe asthma: definition, diagnosis and treatment. Dtsch Arztebl Int 2014;111:847–55PubMedCentralPubMed

Zurück zum Zitat Bush A, Pavord ID. Omalizumab: NICE to USE you, to LOSE you NICE. Thorax 2013;68:7–8CrossRefPubMed Bush A, Pavord ID. Omalizumab: NICE to USE you, to LOSE you NICE. Thorax 2013;68:7–8CrossRefPubMed

Zurück zum Zitat Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343–73CrossRefPubMed Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343–73CrossRefPubMed

Zurück zum Zitat Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2000:CD001186 Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2000:CD001186

Zurück zum Zitat Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol 2015;136:556–68CrossRefPubMed Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol 2015;136:556–68CrossRefPubMed

Zurück zum Zitat Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P et al. Guideline on allergen-specific immunotherapy in IgE mediated allergic diseases — S2k Guideline of the German Society for Aller gology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int 2014;23:282–319PubMedCentralCrossRefPubMed Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P et al. Guideline on allergen-specific immunotherapy in IgE mediated allergic diseases — S2k Guideline of the German Society for Aller gology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int 2014;23:282–319PubMedCentralCrossRefPubMed

Zurück zum Zitat Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014;134:568–75CrossRefPubMed Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014;134:568–75CrossRefPubMed

Zurück zum Zitat de Blay F, Kuna P, Prieto L, Ginko T, Seitzberg D, Riis B et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma-post hoc results from a randomised trial. Respir Med 2014; 108:1430–7CrossRefPubMed de Blay F, Kuna P, Prieto L, Ginko T, Seitzberg D, Riis B et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma-post hoc results from a randomised trial. Respir Med 2014; 108:1430–7CrossRefPubMed

Zurück zum Zitat Berge M van den, Hacken NH ten, Wiel E van der, Postma DS. Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma. Allergy 2013;68:16–26CrossRefPubMed Berge M van den, Hacken NH ten, Wiel E van der, Postma DS. Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma. Allergy 2013;68:16–26CrossRefPubMed

Zurück zum Zitat Vogelmeier C, Kardos P, Hofmann T, Canisius S, Scheuch G, Muellinger B et al. Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. Eur Respir J 2015;45:1273–82CrossRefPubMed Vogelmeier C, Kardos P, Hofmann T, Canisius S, Scheuch G, Muellinger B et al. Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. Eur Respir J 2015;45:1273–82CrossRefPubMed

Zurück zum Zitat Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 2015;372:1987–95CrossRefPubMed Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 2015;372:1987–95CrossRefPubMed

Zurück zum Zitat Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322–9CrossRefPubMed Brusselle GG, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 2013;68:322–9CrossRefPubMed

Zurück zum Zitat Bousquet J, Aubier M, Sastre J, Izquierdo JL, Adler LM, Hofbauer P et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006;61:72–8CrossRefPubMed Bousquet J, Aubier M, Sastre J, Izquierdo JL, Adler LM, Hofbauer P et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006;61:72–8CrossRefPubMed

Zurück zum Zitat Diamant Z, Sidharta PN, Singh D, O’Connor BJ, Zuiker R, Leaker BR et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy 2014;44:1044–52CrossRefPubMed Diamant Z, Sidharta PN, Singh D, O’Connor BJ, Zuiker R, Leaker BR et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy 2014;44:1044–52CrossRefPubMed

Zurück zum Zitat Luu VT, Goujon JY, Meisterhans C, Frommherz M, Bauer C. Synthesis of a high specific activity methyl sulfone tritium isotopologue of fevipiprant (NVP-QAW039). J Labelled Comp Radiopharm 2015;58:188–95CrossRefPubMed Luu VT, Goujon JY, Meisterhans C, Frommherz M, Bauer C. Synthesis of a high specific activity methyl sulfone tritium isotopologue of fevipiprant (NVP-QAW039). J Labelled Comp Radiopharm 2015;58:188–95CrossRefPubMed

Zurück zum Zitat Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309–16CrossRefPubMed Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309–16CrossRefPubMed

Zurück zum Zitat Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med 2013;107:1141–51CrossRefPubMed Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med 2013;107:1141–51CrossRefPubMed

Zurück zum Zitat Lommatzsch M, Korn S, Buhl R, Virchow JC. Against all odds: anti-IgE for intrinsic asthma? Thorax 2014;69:94–6PubMedCentralCrossRefPubMed Lommatzsch M, Korn S, Buhl R, Virchow JC. Against all odds: anti-IgE for intrinsic asthma? Thorax 2014;69:94–6PubMedCentralCrossRefPubMed

Zurück zum Zitat Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2014;2:525–36 e1CrossRefPubMed Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2014;2:525–36 e1CrossRefPubMed

Zurück zum Zitat Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (Ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014;44:1371–85PubMedCentralCrossRefPubMed Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (Ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014;44:1371–85PubMedCentralCrossRefPubMed

Zurück zum Zitat Leckie MJ, Brinke A ten, Khan J, Diamant Z, O’Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144–8CrossRefPubMed Leckie MJ, Brinke A ten, Khan J, Diamant Z, O’Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144–8CrossRefPubMed

Zurück zum Zitat Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973–84PubMedCentralCrossRefPubMed Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973–84PubMedCentralCrossRefPubMed

Zurück zum Zitat Pavord ID, Haldar P, Bradding P, Wardlaw AJ. Mepolizumab in refractory eosinophilic asthma. Thorax 2010;65:370CrossRefPubMed Pavord ID, Haldar P, Bradding P, Wardlaw AJ. Mepolizumab in refractory eosinophilic asthma. Thorax 2010;65:370CrossRefPubMed

Zurück zum Zitat Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–9CrossRefPubMed Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–9CrossRefPubMed

Zurück zum Zitat Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198–207CrossRefPubMed Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198–207CrossRefPubMed

Zurück zum Zitat Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–97CrossRefPubMed Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–97CrossRefPubMed

Zurück zum Zitat Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3:355–66CrossRefPubMed Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3:355–66CrossRefPubMed

Zurück zum Zitat Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014;2:879–90CrossRefPubMed Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014;2:879–90CrossRefPubMed

Zurück zum Zitat Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract 2015;3:167–74CrossRefPubMed Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract 2015;3:167–74CrossRefPubMed

Zurück zum Zitat Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med 2014;20:87–94CrossRefPubMed Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med 2014;20:87–94CrossRefPubMed

Zurück zum Zitat Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088–98CrossRefPubMed Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088–98CrossRefPubMed

Zurück zum Zitat Brightling CE, Chanez P, Leigh R, O’Byrne PM, Korn S, She D et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015;3:692–701CrossRefPubMed Brightling CE, Chanez P, Leigh R, O’Byrne PM, Korn S, She D et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015;3:692–701CrossRefPubMed

Zurück zum Zitat Li W, Gao P, Zhi Y, Xu W, Wu Y, Yin J et al. Periostin: its role in asthma and its potential as a diagnostic or therapeutic target. Respir Res 2015;16:57PubMedCentralCrossRefPubMed Li W, Gao P, Zhi Y, Xu W, Wu Y, Yin J et al. Periostin: its role in asthma and its potential as a diagnostic or therapeutic target. Respir Res 2015;16:57PubMedCentralCrossRefPubMed

Zurück zum Zitat Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455–66CrossRefPubMed Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455–66CrossRefPubMed

Zurück zum Zitat Wenzel S, Wang L, Pirozzi G, Sutherland RE, Graham N, Evans RR et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 Cells/μl. Am J Respir Crit Care Med 2015;191:A6362 Wenzel S, Wang L, Pirozzi G, Sutherland RE, Graham N, Evans RR et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 Cells/μl. Am J Respir Crit Care Med 2015;191:A6362

Zurück zum Zitat Gauvreau GM, O’Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014;370:2102–10CrossRefPubMed Gauvreau GM, O’Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014;370:2102–10CrossRefPubMed

Zurück zum Zitat Cianferoni A, Spergel J. The importance of TSLP in allergic disease and its role as a potential therapeutic target. Expert Rev Clin Immunol 2014;10:1463–74PubMedCentralCrossRefPubMed Cianferoni A, Spergel J. The importance of TSLP in allergic disease and its role as a potential therapeutic target. Expert Rev Clin Immunol 2014;10:1463–74PubMedCentralCrossRefPubMed

Zurück zum Zitat Lommatzsch M. Airway hyperresponsiveness: new insights into the pathogenesis. Semin Respir Crit Care Med 2012;33:579–87CrossRefPubMed Lommatzsch M. Airway hyperresponsiveness: new insights into the pathogenesis. Semin Respir Crit Care Med 2012;33:579–87CrossRefPubMed

Zurück zum Zitat Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010;181:116–24PubMedCentralCrossRefPubMed Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010;181:116–24PubMedCentralCrossRefPubMed

Zurück zum Zitat Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013;132:1295–302PubMedCentralCrossRefPubMed Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013;132:1295–302PubMedCentralCrossRefPubMed

Zurück zum Zitat Pretolani M, Dombret MC, Thabut G, Knap D, Hamidi F, Debray MP et al. Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. Am J Respir Crit Care Med 2014;190:1452–4CrossRefPubMed Pretolani M, Dombret MC, Thabut G, Knap D, Hamidi F, Debray MP et al. Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. Am J Respir Crit Care Med 2014;190:1452–4CrossRefPubMed

Zurück zum Zitat Chakir J, Haj-Salem I, Gras D, Joubert P, Beaudoin ÈL, Biardel S et al. Effects of bronchial thermoplasty on airway smooth muscle and collagen deposition in asthma. Ann Am Thorac Soc 2015 (online first) Chakir J, Haj-Salem I, Gras D, Joubert P, Beaudoin ÈL, Biardel S et al. Effects of bronchial thermoplasty on airway smooth muscle and collagen deposition in asthma. Ann Am Thorac Soc 2015 (online first)

Zurück zum Zitat Lommatzsch M, Virchow JC. The neural underpinnings of asthma. J Allergy Clin Immunol 2007;119:254–5; author reply 5CrossRefPubMed Lommatzsch M, Virchow JC. The neural underpinnings of asthma. J Allergy Clin Immunol 2007;119:254–5; author reply 5CrossRefPubMed

Zurück zum Zitat Kirby M, Ohtani K, Lopez Lisbona RM, Lee AM, Zhang W, Lane P et al. Bronchial thermoplasty in asthma: 2-year follow-up using optical coherence tomography. Eur Respir J 2015;46:859–62CrossRefPubMed Kirby M, Ohtani K, Lopez Lisbona RM, Lee AM, Zhang W, Lane P et al. Bronchial thermoplasty in asthma: 2-year follow-up using optical coherence tomography. Eur Respir J 2015;46:859–62CrossRefPubMed

Zurück zum Zitat Mosen DM, Schatz M, Magid DJ, Camargo CA Jr. The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol 2008;122:507–11 e6CrossRefPubMed Mosen DM, Schatz M, Magid DJ, Camargo CA Jr. The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol 2008;122:507–11 e6CrossRefPubMed

Zurück zum Zitat Pakhale S, Baron J, Dent R, Vandemheen K, Aaron SD. Effects of weight loss on airway responsiveness in obese adults with asthma: does weight loss lead to reversibility of asthma? Chest 2015;147:1582–90CrossRefPubMed Pakhale S, Baron J, Dent R, Vandemheen K, Aaron SD. Effects of weight loss on airway responsiveness in obese adults with asthma: does weight loss lead to reversibility of asthma? Chest 2015;147:1582–90CrossRefPubMed

Zurück zum Zitat Huisstede A van, Rudolphus A, Castro Cabezas M, Biter LU, van de Geijn GJ, Taube C et al. Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax 2015;70:659–67CrossRefPubMed Huisstede A van, Rudolphus A, Castro Cabezas M, Biter LU, van de Geijn GJ, Taube C et al. Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax 2015;70:659–67CrossRefPubMed